Literature DB >> 7758095

Migraine patients experience poorer subjective well-being/quality of life even between attacks.

C G Dahlöf1, E Dimenäs.   

Abstract

The aim of the present study was to compare the general well-being of migraine patients between attacks with that of an age- and sex-matched control group. One hundred and forty-five consecutive and eligible patients at the Gothenburg Migraine Clinic were asked about their well-being and their complaints. Using three self-administered standardized questionnaires, the Minor Symptoms Evaluation Profile (MSEP), Subjective Symptoms Assessment Profile (SSAP) and the Psychological General Well-Being (PGWB) Index, evaluable responses were obtained from 138 migraine patients. Compared with control subjects, migraineurs perceived more symptoms and greater emotional distress as well as disturbed contentment, vitality and sleep. It is concluded that the general well-being of the migraine patient is impaired, even between the attacks.

Entities:  

Mesh:

Year:  1995        PMID: 7758095     DOI: 10.1046/j.1468-2982.1995.1501031.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  27 in total

Review 1.  The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research.

Authors:  Wayne N Burton; Stephen H Landy; Kristen E Downs; M Chris Runken
Journal:  Mayo Clin Proc       Date:  2009-05       Impact factor: 7.616

Review 2.  [Sphincter of Oddi dyskinesia].

Authors:  H-D Allescher
Journal:  Internist (Berl)       Date:  2015-06       Impact factor: 0.743

Review 3.  Sumatriptan. A pharmacoeconomic review of its use in migraine.

Authors:  A J Coukell; H M Lamb
Journal:  Pharmacoeconomics       Date:  1997-05       Impact factor: 4.981

Review 4.  Burden of migraine. A review of its socioeconomic impact.

Authors:  G D Solomon; K L Price
Journal:  Pharmacoeconomics       Date:  1997       Impact factor: 4.981

5.  Comparison of expected outcomes between patients and neurologists using Kano's methodology in symptomatic migraine treatment.

Authors:  J Matías-Guiu; M T Caloto; G Nocea
Journal:  Patient       Date:  2012       Impact factor: 3.883

6.  The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care.

Authors:  André Pradalier; Michel Lantéri-Minet; Gilles Géraud; Hervé Allain; Christian Lucas; Antonio Delgado
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  Migraine and functional impairment.

Authors:  Jan Lewis Brandes
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

Review 8.  Sumatriptan. An updated review of its use in migraine.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

Review 9.  Impact of headache in Europe: a review for the Eurolight project.

Authors:  Lars Jacob Stovner; Colette Andrée
Journal:  J Headache Pain       Date:  2008-04-17       Impact factor: 7.277

10.  The Development and Psychometric Properties of the MSQOL: A Migraine-Specific Quality-of-Life Instrument.

Authors:  S P McKenna; L C Doward; K M Davey
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.